SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 42 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $363,000 | +63.5% | 39,754 | -0.0% | 0.00% | – |
| Q4 2018 | $222,000 | -77.0% | 39,770 | -51.0% | 0.00% | – |
| Q3 2018 | $966,000 | +48.2% | 81,160 | +27.1% | 0.00% | – |
| Q2 2018 | $652,000 | +28.3% | 63,861 | +63.1% | 0.00% | – |
| Q1 2018 | $508,000 | +71.6% | 39,157 | +28.5% | 0.00% | – |
| Q4 2017 | $296,000 | -37.2% | 30,470 | -4.8% | 0.00% | – |
| Q3 2017 | $471,000 | -14.8% | 31,994 | -7.0% | 0.00% | – |
| Q2 2017 | $553,000 | +657.5% | 34,390 | +646.3% | 0.00% | – |
| Q1 2017 | $73,000 | +30.4% | 4,608 | 0.0% | 0.00% | – |
| Q4 2016 | $56,000 | – | 4,608 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |